Vor Biopharma (VOR) Form 144 shows large June–July sales and an 18,382-share filing
Rhea-AI Filing Summary
Vor Biopharma Inc. (VOR) Form 144 disclosure shows a proposed sale of 18,382 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $36,407.39 and an approximate sale date of 08/11/2025 on NASDAQ. The filing records that these shares were acquired as restricted stock on 08/01/2025 (12,696 shares) and 08/06/2025 (5,686 shares).
The notice also lists multiple sales by Robert Ang in June–July 2025 totaling 1,134,988 shares with gross proceeds of about $2,544,405.10. Several issuer and filer identification fields (including issuer name and filer CIK) are left blank in the form.
Positive
- Disclosure of broker and exchange used for the proposed sale: Morgan Stanley Smith Barney LLC on NASDAQ
- Transaction specifics provided: number of shares, aggregate market value, and acquisition dates for the shares proposed to be sold
Negative
- Extensive recent insider sales reported: 1,134,988 shares sold in June–July 2025 for gross proceeds of about $2,544,405.10
- Key identification fields missing: the filing content omits the issuer name and filer CIK as presented
- Filer relationship to issuer not stated in the provided content, limiting context for the sales
Insights
TL;DR: The filing discloses a small proposed sale of recently acquired restricted shares and large prior sales by Robert Ang totaling over one million shares.
The Form 144 identifies a proposed sale of 18,382 shares valued at $36,407.39 to be executed via Morgan Stanley Smith Barney LLC on NASDAQ. The same shares were acquired as restricted stock on 08/01/2025 and 08/06/2025. The document separately reports numerous prior sales by Robert Ang in June–July 2025 aggregating 1,134,988 shares for gross proceeds of approximately $2,544,405.10. These explicit figures are relevant to liquidity and insider selling patterns.
TL;DR: The filing provides clear transaction details but omits issuer and filer identification fields, reducing transparency.
The form documents broker, exchange, acquisition dates, and transaction amounts, which supports regulatory disclosure. However, key fields such as the issuer name and filer CIK are blank in the provided content, and the filer’s relationship to the issuer is not stated. For governance and compliance review, those omissions are noteworthy because they limit immediate verification of insider status and context for the reported sales.